The laboratory testing market is huge. According to a study
conducted by Quest Diagnostics, the largest clinical testing laboratory in the
U.S., the laboratory testing market in the United States is approximately $50
billion. Of that, 60% is controlled by hospital-based laboratories. Another 35%
of the market is held by independent clinical laboratories, and physician
office laboratories (POLs) hold the remaining 5%. Within this $50 billion
market, most of the testing performed is for routine lab tests (such as total
cholesterol, pap testing and white blood cell count) and anatomic pathology
tests. Anatomic pathology tests attempt to identify abnormalities in body
organs that signal the advent of disease as opposed to the more routine
procedures that test blood and other bodily fluids. However, recently there has
been a dramatic increase in gene-based testing and molecular testing, which
measure our susceptibilities to inherited diseases, and esoteric testing.
Esoteric testing is a catchall term for more complex clinical tests.
In the vanguard of the forces advancing women’s health
through these technologies marches Avant Diagnostics, Inc. (OTCQB: AVDX).
Employing technology it has exclusively licensed from Wayne State University,
the company has developed a microarray-based diagnostic test called OvaDx.
OvaDx is the first large panel biomarker monitoring test for ovarian cancer. It
measures the activation of the immune system in blood samples in response to
early stage ovarian tumor cell development. A biomarker is simply an objective
measure of the body’s functioning.
Microarrays have been described as the tracks of the global
life sciences freight train. A microarray is a collection of DNA on a surface.
They are sometimes referred to as biochips or DNA chips. In the forefront of
microarray technology is the Arrayit Corporation (OTC: ARYC), and back in 2009,
Avant entered into a Technology Transfer Agreement (TTA) with Arrayit. The TTA
gave Avant exclusive license rights to all of Arrayit’s trade secrets and
protocols required for the sale and use of the OvaDx ovarian cancer test.
Arrayit Corporation is a leader in the microarray industry. It develops,
manufactures and markets life science tools and integrated laboratory platforms
for the analysis of genetic variation, biological function, and diagnostics.
Arrayit also provides specialized equipment, tools, and microarray
manufacturing services to more than 10,000 research laboratories,
pharmaceutical companies, academic institutions, clinical research
organizations, government agencies and biotechnology companies around the
globe.
Microarrays have indeed proved to be a track to success, and
at least three companies, Illumina, Inc. (NASDAQ: ILMN), Agilent Technologies,
Inc. (NYSE: A) and Myriad Genetics, Inc. (NASDAQ: MYGN) have taken that track.
Myriad deserves special mention. The company’s valuation rose spectacularly
after it was revealed that Angelina Jolie had used Myriad’s diagnostic test,
BRACAnalysis. BRACAnalysis determined that Jolie had an 87 percent risk of
breast cancer and 50 percent chance of ovarian cancer because of an inherent
genetic mutation. Miss Jolie has a defect in her BRACI genes. Those with a
similar defect have, on average, a 65% chance of developing breast cancer.
Myriad got its microarray technology from Arrayit, the same company that has
given Avant access to its methodologies.
Avant is in the right place at the right time. The molecular
diagnostics segment of the laboratory testing market is expected to reach $8
billion by the end of 2017. OvaDx is now undergoing 510(K) trials. A 510(K) is
a pre-market submission made to the FDA to demonstrate that the device to be
marketed is at least as safe and effective as a legally marketed device. Avant
believes the OvaDx test has an advantage over Roche’s CA-125 test and
Vermillion’s Ova 1 test. With its gene-based microarray OvaDX test, Avant is
not only guarding our womenfolk, it’s poised to enjoy great financial success.
It’s a classic case of having your cake and eating it, too.
For more information, visit www.avantdiagnostics.com
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment